B A C K G R O U N D
Before vaccination against measles was available, annual case numbers were estimated at 130 million (WHO 1999) , and the disease caused between five and eight million deaths globally each year (Moss 2009). With the introduction of the vaccine, the worldwide number of cases began to decline (WHO 1999 ) and this trend continued with increasing vaccination coverage (WHO 2009a). However, the number of measles cases worldwide exceeded 300,000 in 2010 (WHO 2011) 
Description of the condition
Measles is a highly communicable viral illness (Heymann 2008). The measles virus is an enveloped, single-stranded RNA Morbillivirus of the family Paramyxoviridae (Heymann 2008; WHO 2009a). The virus is shed from the respiratory tract of infected persons and transmitted by aerosolised droplets or by direct contact with respiratory secretions (WHO 2009a) . Someone with measles is contagious from one day before the symptoms start until four days after the rash appears. A susceptible person exposed to measles will usually develop symptoms after around 10 days but this may range from 7 to 18 days after exposure (Heymann 2008). Symptoms of measles include fever, conjunctivitis, runny nose, cough and a red blotchy rash (WHO 1999) . The illness is often more severe in infants and adults than in children (Heymann 2008) . Complications occur more frequently in cases in low-income rather than high-income countries (75% or more versus 10% to 15% of cases, respectively) (WHO 1999). Middle ear infection and pneumonia are fairly common complications, occurring in 5% to 15%, and 5% to 10% of children with measles, respectively (WHO 2009a). Encephalitis is a serious, but rarer, complication of measles, occurring in about 1 out of every 1000 cases (WHO 2009a) . A slowly progressing neurological disease, subacute sclerosing panencephalitis (SSPE), very rarely (1 out of 100,000 cases) occurs several years after the original measles infection, most often in children infected with measles under the age of two years (Heymann 2008).
Description of the intervention
The practice of passive immunisation against measles has been A systematic review of the evidence of effectiveness of passive immunisation for the post-exposure prophylaxis of measles would help to clarify the effectiveness rate and the minimum effective dose and identify differences in benefit or harm across population groups. These outcomes would be valuable to guide public health practice in countries with low incidences of measles.
How the intervention might work

Why it is important to do this review
O B J E C T I V E S
To assess the effectiveness and safety of intramuscular injection or intravenous infusion of immunoglobulins for preventing measles when administered to exposed susceptible people before the onset of symptoms.
M E T H O D S Criteria for considering studies for this review Types of studies
We will include randomised controlled trials (RCTs), quasi-RCTs and prospective non-RCTs (cohort studies), irrespective of blinding, publication status, language or unit of randomisation. We will include prospective non-RCTs given that more recent studies, using current immunoglobulin preparations, are likely to be nonrandomised for ethical reasons. The intervention has been part of public health practice since the 1930s and as such, any RCTs are likely to have been conducted at a time when the antibody levels of blood donors were due to infection with measles rather than vaccination. To inform practice appropriately, any evidence of the effectiveness of current immunoglobulin preparations should be included.
Types of participants
People of any age, sex or ethnic origin who were susceptible (no history of measles and not vaccinated against measles and/or measles immunoglobulin G (IgG) negative) and exposed to measles virus or exposed to someone diagnosed with measles, and who were asymptomatic at the time of intervention or control administration. The primary study's definition of 'exposed' will be accepted and any differences explored via subgroup analysis.
Types of interventions
1. Intervention: intramuscular injection of polyclonal immunoglobulins; intravenous infusion of polyclonal immunoglobulins.
2. Control: no intervention or placebo or live attenuated measles virus vaccine. We will also include studies assessing different brands or preparations of polyclonal immunoglobulins or different dosages of immunoglobulins. We will only include studies where the intervention (and control) are administered to participants after exposure to measles and before the participants develop measles symptoms.
Types of outcome measures
Primary outcomes 1. Cases of measles. The diagnosis may be made by detection or isolation of measles virus in urine or respiratory secretions; by detection of measles virus antigen in urine or respiratory secretions; by serological detection of immunoglobulin M (IgM) to measles in the absence of vaccination eight days to eight weeks prior to testing; by IgG seroconversion or by a fourfold or greater rise in titre to measles virus in the absence of vaccination eight days to eight weeks prior to testing; or by symptoms consistent with measles (fever, a red blotchy rash, conjunctivitis, runny nose and cough) or modified measles (prolonged incubation period, milder fever, cough, runny nose, conjunctivitis and sparse discrete rash of short duration).
2. Mortality due to measles.
Secondary outcomes
1. Prevention of measles outbreak (higher than expected incidence) as identified by active surveillance.
2. Cessation of measles outbreak (return to expected incidence) as identified by active and/or passive surveillance.
3. Complications due to measles such as otitis media, pneumonia or encephalitis.
4. Occurrence and type of adverse events. We will analyse two types of adverse events: serious adverse events and non-serious adverse events. A serious adverse event is "any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/ incapacity, or is a congenital anomaly/birth defect" (EMEA 1995). We will classify all other events as non-serious. We will specifically extract data on: blood-borne virus infection; anaphylaxis; generalised hypersensitivity; and injection site reactions. We will also include any other adverse event reported as such by study authors.
Search methods for identification of studies Electronic searches
We will search the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, current issue at the time), which contains the Cochrane Acute Respiratory Infections (ARI) Group's Specialised Register, MEDLINE (1946 to present), CINAHL (1981 to present) and EMBASE (1980 to present). We will use the search strategy in Appendix 1 to search MEDLINE and CENTRAL. We will adapt the strategy for the other databases. We will combine the MEDLINE and CENTRAL searches with the filter for study type in Appendix 2 only if the search results retrieved are too large to be manageable. We will adapt the filter as necessary for the other databases.
Searching other resources
We will search reference lists of identified relevant studies and reviews. To locate further published or unpublished studies, we will attempt to contact companies manufacturing immunoglobulin products for countries with low measles incidences and attempt to contact the corresponding author of any included studies.
Data collection and analysis
Selection of studies
Two review authors (MY, GN) will independently inspect the title and abstract (as available) of each reference identified by the search and determine the potential relevance of each article. If identified by either review author as potentially relevant, we will retrieve the full article. Both review authors will inspect each full article independently, using an eligibility checklist based on the inclusion criteria, to determine inclusion in the review. We will resolve any disagreements through discussion, or by consulting a third review author (AC). We will exclude studies not meeting the eligibility criteria and we will state the reasons for exclusion. We will list duplicate publications with the main publication for included studies. We will attempt to write to corresponding authors if uncertainties about duplicate publications exist.
Data extraction and management
Two review authors (MY, AC) will independently extract data from the included studies using pre-designed data extraction forms. We will resolve disagreement by discussion, or by a third review author (GN), independently extracting the data, as necessary. We will attempt to contact study authors for clarification or further information as necessary. We will extract the following data.
1. The study i) First author, publication year/not published. ii) Location. iii) Date study undertaken. iv) Randomised/quasi-randomised/non-randomised. 2. Participants i) Number in each group. ii) Age range in each group. iii) Proportion of adults, children, infants (aged < one year) in each group. iv) Gender distribution in each group. v) Proportion of high risk individuals in each group: those with immunodeficiency; pregnancy or age under one year. vi) Range of time since exposure in each group. vii) Average time since exposure in each group. viii) Any measure of baseline comparability and result of this, if calculated.
3. Intervention i) Intervention group: product used, concentration of measles antibody if known, volume given, route of administration.
ii) Control group: placebo/vaccine/product/other, concentration of measles antibody if relevant and known, volume given, route of administration.
4. Outcomes i) Primary and secondary (as above).
ii) Length of follow-up. iii) Loss to follow-up.
Assessment of risk of bias in included studies
Two review authors (MY, AC) will independently assess the risk of bias for included studies. We will resolve any disagreements by discussion or by including a third review author (GN) as needed. For randomised and quasi-randomised studies, we will assess: randomisation sequence generation; allocation concealment; blinding of participants, personnel and outcome assessors; incomplete outcome data; drop-out/selective reporting; and other potential sources of bias. We will report the risk of bias using The Cochrane Collaboration's tool for assessing 'Risk of bias' (Higgins 2011). For non-randomised studies, allocation concealment is not applicable. We will therefore assess: blinding of participants, personnel and outcome assessors; incomplete outcome data; drop out/ selective reporting; group differences at baseline; management of confounders and other potential sources of bias. We will report the risk of bias using a modified version of the risk of bias tool (Higgins 2011).
Measures of treatment effect
Outcomes, as identified above, are dichotomous. We will express these outcomes as risk ratios (RRs) and calculate 95% confidence intervals (CIs) for each.
Unit of analysis issues
Should cluster-randomised trials be included in the review, we will attempt to extract RRs and 95% CIs resulting from analyses that have accounted for the clustering directly from the paper(s). If this is possible, we will proceed to meta-analyse the data using the inverse variance method. If this is not possible, we will extract the number of clusters, the average size of each cluster, the outcome data at the level of the individuals and an estimate of the intracluster correlation coefficient and proceed to reduce the trial(s) to their 'effective sample size' for meta-analysis (Higgins 2011). Should studies with multiple intervention groups, for example different doses of immunoglobulins compared to control, be included in the review, we will calculate a weighted average of the relevant pair-wise comparisons from the study and a variance for the study, taking into account the correlation between the comparisons.
Dealing with missing data
We will attempt to contact the trial authors for any missing data.
Where missing data exceeds 20%, or where data are clearly missing in different proportions in the treatment groups (P < 0.05), we will exclude the study from further assessment of the relevant outcome.
For smaller amounts of missing data, we will undertake sensitivity analysis after assuming worst case and best case scenarios.
Assessment of heterogeneity
We will explore the presence of heterogeneity firstly by comparing studies' population groups and interventions. If heterogeneity is clear, we will not proceed to meta-analysis. If there is no obvious heterogeneity, we will proceed to meta-analysis and consider the forest plot for each primary outcome and the secondary outcome, "serious adverse events". If statistical heterogeneity is clear visually, we will proceed to subgroup and sensitivity analyses and reexamine the heterogeneity of these results separately. If heterogeneity is not obvious in the initial forest plots, we will consider the Cochrane Chi 2 test and I 2 statistic for each outcome. We will consider an I 2 estimate of 60% or more, alongside a Chi 2 P value of 0.1 or less important heterogeneity and again proceed to subgroup and sensitivity analyses. If heterogeneity is not explained by subgroup or methodological differences, we will report the results of a random-effects model for the relevant outcome(s).
Assessment of reporting biases
In the event of multiple publications of the same study, we will list the subsequent papers with the main paper and only enter data once. If uncertainty exists in this respect, we will attempt to contact the study authors. We will assess publication bias by examining funnel plots if we have sufficient studies (at least 10).
Data synthesis
We will calculate the RR and 95% CI for each outcome measured in each study. We will use the fixed-effect model for each primary outcome and the secondary outcome, "serious adverse events" and examine the forest plots to assess heterogeneity. We will then explore possible reasons for apparent heterogeneity via subgroup and sensitivity analyses. If these do not explain the apparent heterogeneity, we will use a random-effects model to analyse the pooled studies and report this result. If heterogeneity is minimal, or explained by subgroup or sensitivity analyses, we will report these using a fixed-effect model. Even in the absence of apparent significant heterogeneity for the primary outcome of "cases of measles", we will proceed to subgroup and sensitivity analysis if we have a sufficient number of included studies. We will report the results of the other secondary outcomes descriptively.
Subgroup analysis and investigation of heterogeneity
For subgroup analysis we will include:
• study type;
• age of participants (infants/children/adults/combinations);
• proportion of high risk individuals (pregnant plus immunodeficient plus aged under one year);
• dose of immunoglobulins;
• dose of measles-specific immunoglobulins;
• route of administration of immunoglobulins;
• timing of administration of intervention in relation to exposure; and
• differences in primary study definitions of 'exposed' if necessary.
Sensitivity analysis
For sensitivity analysis we will include:
• risk of bias of included studies; and
• studies with imputed missing data.
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